SCHEMBL4270182

SCHEMBL4270182

CC(C)OC(=O)OCC(OC1(Cn2cnc3c(O)nc(N)nc32)CC1)P(=O)(O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAP Q12884 2/20 0.37
HPRT1 P00492 5/20 0.33
CYP3A4 P08684 1/20 0.32
CCNE1 P24864 2/20 0.32
CDK2 P24941 2/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
ADRA1A P35348 1/20 0.31
HSD17B10 Q99714 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
HDAC1 Q13547 2/20 0.31
HDAC2 Q92769 2/20 0.31
HDAC8 Q9BY41 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
POLB P06746 1/20 0.31
SERPINA3 P01011 1/20 0.30
CDK1 P06493 1/20 0.30
CCNB1 P14635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942828 0.90 FAP (0.35) FAPCCNE1CDK2KDM4EALDH1A1
SCHEMBL4273076 0.89 HPRT1 (0.31) HPRT1KDM4EALDH1A1HPGDADRA1A
SCHEMBL4267905 0.88 FAP (0.36) FAPHPRT1CYP3A4CCNE1CDK2
SCHEMBL4274826 0.88 FAP (0.36) FAPHPRT1CYP3A4CCNE1CDK2
SCHEMBL4266050 0.87 CYP2C19 (0.33) HPRT1CYP3A4CCNE1CDK2HDAC1
SCHEMBL4274985 0.87 KDM4E (0.45) FAPKDM4EALDH1A1HPGDADRA1A
SCHEMBL4265957 0.84 FAP (0.53) FAPCYP3A4ALDH1A1
SCHEMBL3292459 0.84 FAP (0.36) FAPHPRT1CCNE1CDK2HSP90AA1
SCHEMBL4279937 0.83 HK1 (0.35) FAPHSP90AA1HSP90AB1CYP2C19HK1
SCHEMBL2942826 0.82 FAP (0.35) FAPCCNE1CDK2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605147-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2009-10-20 US claimed
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same CHO DONG-GYU 2006-12-28 US claimed
US-7605147-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2009-10-20 US disclosed
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same CHO DONG-GYU 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same PNP, ITPA, MTAP FAP 2016/4885HPRT1 34/4885CYP3A4 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.